Premium
ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE‐155 STUDY
Author(s) -
Gregory G.,
Walker P.,
Mahadevan D.,
Wang D.,
Chang J.,
HernandezIlizaliturri F.,
Klein A.,
Rybka W.,
WagnerJohnston N.,
Escobar C.,
Pagel J.M.,
Mohrbacher A.,
Opat S.,
Shortt J.,
Ma H.,
Gwo J.,
Farooqui M.,
Quach H.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.140_2630
Subject(s) - medicine , tolerability , pembrolizumab , neutropenia , clinical endpoint , phases of clinical research , febrile neutropenia , diffuse large b cell lymphoma , oncology , interim analysis , nausea , adverse effect , surgery , lymphoma , clinical trial , toxicity , cancer , immunotherapy